CAMBRIDGE, Mass. & PARIS--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX - News) and Fovea Pharmaceuticals, SA ("Fovea") announced today that they have entered into an exclusive license agreement for the ...
Genzyme and Paris-based Fovea Pharmaceuticals have forged a collaboration to develop gene therapies for blindness. The cross-Atlantic pact will match Genzyme's expertise in protein production and gene ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback